{"title":"氟西汀缓释剂 90 毫克/周在精神病学中的疗效和安全性:基于证据的微型综述","authors":"Niayesh Mohebbi, M. Motamed, Mahsa Panahishokouh","doi":"10.5812/ijpbs-146023","DOIUrl":null,"url":null,"abstract":"Context: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of various psychiatric disorders. While the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. This mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. Evidence Acquisition: A comprehensive literature search was conducted using electronic databases (PubMed and Embase) to identify relevant studies published until July 2023. Studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. The identified studies were critically appraised for their methodology and quality. Results: Limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. However, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), premature ejaculation, and premenstrual dysphoric disorder. These studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. Conclusions: Once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.","PeriodicalId":46644,"journal":{"name":"Iranian Journal of Psychiatry and Behavioral Sciences","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Efficacy and Safety of Fluoxetine Delayed-Release 90 mg/Weekly in Psychiatry: An Evidence-Based Mini-Review\",\"authors\":\"Niayesh Mohebbi, M. Motamed, Mahsa Panahishokouh\",\"doi\":\"10.5812/ijpbs-146023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Context: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of various psychiatric disorders. While the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. This mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. Evidence Acquisition: A comprehensive literature search was conducted using electronic databases (PubMed and Embase) to identify relevant studies published until July 2023. Studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. The identified studies were critically appraised for their methodology and quality. Results: Limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. However, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), premature ejaculation, and premenstrual dysphoric disorder. These studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. Conclusions: Once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.\",\"PeriodicalId\":46644,\"journal\":{\"name\":\"Iranian Journal of Psychiatry and Behavioral Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Psychiatry and Behavioral Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/ijpbs-146023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Psychiatry and Behavioral Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijpbs-146023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
The Efficacy and Safety of Fluoxetine Delayed-Release 90 mg/Weekly in Psychiatry: An Evidence-Based Mini-Review
Context: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of various psychiatric disorders. While the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. This mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. Evidence Acquisition: A comprehensive literature search was conducted using electronic databases (PubMed and Embase) to identify relevant studies published until July 2023. Studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. The identified studies were critically appraised for their methodology and quality. Results: Limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. However, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), premature ejaculation, and premenstrual dysphoric disorder. These studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. Conclusions: Once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.
期刊介绍:
The Iranian Journal of Psychiatry and Behavioral Sciences (IJPBS) is an international quarterly peer-reviewed journal which is aimed at promoting communication among researchers worldwide and welcomes contributions from authors in all areas of psychiatry, psychology, and behavioral sciences. The journal publishes original contributions that have not previously been submitted for publication elsewhere. Manuscripts are received with the understanding that they are submitted solely to the IJPBS. Upon submission, they become the property of the Publisher and that the data in the manuscript have been reviewed by all authors, who agree to the analysis of the data and the conclusions reached in the manuscript. The Publisher reserves copyright and renewal on all published material and such material may not be reproduced without the written permission of the Publisher. Statements in articles are the responsibility of the authors.